announced that three tubes of its Ameluz topical gel, in combination with photodynamic therapy, exhibited a positive safety profile when used to treat facial and scalp actinic keratosis, reported ROTH Capital Partners analyst Dr. Jonathan Aschoff in an August 28 research note.
The currently approved dose in the States is one tube.
278% Return Implied
ROTH reiterated its price target on the Massachusetts-based biopharma of US$33 per share. Biofrontera's current share price, in comparison, is about US$8.72. Given these figures, the projected potential return for investors is material, at 278%.
Biofrontera is a Buy.
New Safety Data
Aschoff summarized the findings of the recent Phase 1 clinical trial, in which treatment using three tubes of Ameluz and photodynamic therapy administered via the company's RhodoLED XL lamp was evaluated for safety and tolerability.
None of the patients reported any serious adverse events or quit the study because of a treatment-associated adverse event.
The adverse events that did occur were expected due to "the therapeutic principle of photodynamic therapy," wrote Aschoff, and were consistent with those linked to the use of one tube of Ameluz in the same indication. Typically, effects that occurred resolved in one to four days after photodynamic therapy but sometimes lasted one to two weeks.
Overall, patients tolerated treatment well.
Pursuit of Label Expansion
Biofrontera intends to submit these safety data to the U.S. Food and Drug Administration, in Q4/23, to support expansion of its Ameluz label to include use of up to three tubes per treatment, Aschoff reported.
An expansion, the analyst added, would make "Ameluz more competitive, given the ability to treat more surface area per treatment." Therefore, treatment could be administered in fewer office visits, another positive.
Already, Ameluz differentiates itself from competitors, Aschoff pointed out, because it is the only treatment of this type in which the drug is administered broadly over a field versus being applied to individual keratoses.
"The treatment is particularly effective because the procedure treats both visible actinic keratosis lesions as well as invisible lesions that lie within the field defined by the visible lesions," explained Aschoff. "This application difference is part of why Ameluz's efficacy is unmatched by competitors."
More Data Early Next Year
In other news, Biofrontera has advanced the Phase 3 trial assessing Ameluz plus photodynamic therapy in basal cell carcinoma to the point where the last of the 187 enrolled patients will complete final assessment in Q1/24, Aschoff noted.
Data readout should happen soon afterward.
|Want to be the first to know about interesting Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter.
- Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor.
- This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.
Disclosures for Roth, Biofrontera Inc., August 28, 2023
Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Disclosures: ROTH makes a market in shares of Biofrontera, Inc. and as such, buys and sells from customers on a principal basis. ROTH and/or its employees, officers, directors and owners own options, rights or warrants to purchase shares of Biofrontera, Inc. stock.
ROTH Capital Partners, LLC expects to receive or intends to seek compensation for investment banking or other business relationships with the covered companies mentioned in this report in the next three months. The material, information and facts discussed in this report other than the information regarding ROTH Capital Partners, LLC and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This report should not be used as a complete analysis of the company, industry or security discussed in the report. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this report are subject to change without notice. An investment in the stock may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, an investment in the stock may involve a high degree of risk and may not be suitable for all investors. No part of this report may be reproduced in any form without the express written permission of ROTH. Copyright 2023. Member: FINRA/SIPC.